Differential treatment effects on beta-cell function using model-based parameters in type 2 diabetes: results from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) 2025

Limitations in achieving glycemic targets from CGM data and persistence of severe hypoglycemia in adults with type 1 diabetes regardless of insulin delivery method 2025

-cell function over time on glycemic outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy 2024

Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus 2024

Relationship between average glucose levels and HbA1c differs across racial groups: a substudy of the GRADE randomized trial 2024

Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey 2024

The use of rescue insulin in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE) 2024

Care management processes important for high-quality diabetes care 2023

Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011-2020 2023

Safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes: from injections to hybrid closed-loop therapy 2023

Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC Study 2022

Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial 2022

Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes 2021

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial 2021

The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin 2021

Redesigning primary care to improve diabetes outcomes (the UNITED Study) 2020

. 2018;41:2275-2280 2019

Validation of time in range as an outcome measure for diabetes clinical trials 2019

Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery 2019

Baseline characteristics of the Vitamin D and type 2 Diabetes (D2d) study: a contemporary prediabetes cohort that will inform diabetes prevention efforts 2018

Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring 2018

2017;40:777-83 2017

Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial 2017

Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections 2017

Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1) 2017

REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes 2017

Response to Comment on Pathak et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011 2017

The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading 2017

2016 Health Care & Education presidential address: if DSME were a pill, would you prescribe it? 2016

Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial 2016

Durability of addition of roux-en-Y gastric bypass to lifestyle intervention and nedical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild to moderate obesity: A randomized control trial 2016

Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial 2016

Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery 2016

Racial differences in and prognostic value of biomarkers of hyperglycemia 2016

Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes 2016

Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011 2016

Clinical utility of SMBG: recommendations on the use and reporting of SMBG in clinical research 2015

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange Clinic registry 2015

Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes 2015

Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! 2015

Insulin dose and cardiovascular mortality in the ACCORD Trial 2015

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group 2015

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes 2015

New insulin Glargine 300 Units/mL versus Glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4) 2015

Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis 2015

Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry 2015

A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes 2014

Depression in adults in the T1D Exchange Clinic Registry 2014

Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine 2014

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) 2014

Novel use and utility of integrated electronic health records to assess rates of prediabetes recognition and treatment: brief report from an integrated electronic health records pilot study 2014

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial 2014

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial 2014

Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes 2014

Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry 2014

Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial 2014

Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes 2013

Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study 2013

Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry 2013

Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants 2013

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes 2013

Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies 2013

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial 2013

No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes 2013

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes 2012

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes 2012

Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy 2012

Diabetes and lung cancer among postmenopausal women 2012

Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial 2012

Increased mortality of patients with diabetes reporting severe hypoglycemia 2012

Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial 2012

National standards for diabetes self-management education 2012

Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association 2012

Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial 2012

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants 2012

Diabetes performance measures: current status and future directions 2011

Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial 2011

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase 2011

American Diabetes Association. Standards of medical care in diabetes--2010 2010

Diabetes and cancer: a consensus report 2010

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial 2010

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits 2010

Simulated physician learning program improves glucose control in adults with diabetes 2010

Customized feedback to patients and providers failed to improve safety or quality of diabetes care: a randomized trial 2009

National standards for diabetes self-management education 2009

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial 2009

Simulated physician learning intervention to improve safety and quality of diabetes care: a randomized trial 2009

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine 2008

Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative 2008

Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents 2008

Improving diabetes care in practice: findings from the TRANSLATE trial 2008

Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care 2008

National standards for diabetes self-management education 2008

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study 2006

Thiazolidinediones: the case for early use 2006

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia 2005

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea 2005

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial 2005

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial 2005

Randomized trial of quality improvement intervention to improve diabetes care in primary care settings 2005

Diabetes management in correctional institutions 2004

Is patient readiness to change a predictor of improved glycemic control? 2004

Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing 2003

Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia 2003

Use of an automated device for alternative site blood glucose monitoring 2001

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes 2000

A joint venture with the commonwealth of independent states 1993

The Glucose Management Indicator: time to change course [editorial]?.  47. 2024

Continuous glucose monitoring-derived data report-simply a better management tool [editorial].  43. 2020

Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes [editorial].  43. 2020

Glucose management indicator (GMI): insights and validation using Guardian 3 and Navigator 2 sensor data [editorial].  42. 2019

Racial/ethnic disparities in the prevalence of diabetes and prediabetes by BMI: Patient Outcomes Research To Advance Learning (PORTAL) multisite cohort of adults in the U.S [editorial].  42. 2019

Continuous glucose monitoring in patients with type 1 diabetes using insulin injections [editorial].  39. 2016

Response to Comment on Powers et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics [editorial].  39. 2016

Trends in insulin use and diabetes control in the U.S.: 1988-1994 and 1999-2012 [editorial].  39. 2016

Strategies to reduce the cost of renal complications in patients with type 2 diabetes [editorial].  34. 2011

The growing importance of diabetes screening [editorial].  33. 2010

Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association [review] 2022

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group [review] 2020

Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association [review] 2020

Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time-in-Range [review] 2019

2017 National standards for diabetes self-management education and support [review] 2017

Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [review] 2017

International consensus on use of continuous glucose monitoring [review] 2017

Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics [review article] 2015

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [review] 2012

National standards for diabetes self-management education [review] 2011

National standards for diabetes self-management education [review] 2010

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review] 2009

0149-5992

1935-5548